BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 16194824)

  • 1. Gene expression profiling in breast cancer: towards individualising patient management.
    Murphy N; Millar E; Lee CS
    Pathology; 2005 Aug; 37(4):271-7. PubMed ID: 16194824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
    Correa Geyer F; Reis-Filho JS
    Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial biomarker expression in breast cancer.
    Rakha EA; Reis-Filho JS; Ellis IO
    Breast Cancer Res Treat; 2010 Apr; 120(2):293-308. PubMed ID: 20107892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarrays in breast cancer research and clinical practice--the future lies ahead.
    Gruvberger-Saal SK; Cunliffe HE; Carr KM; Hedenfalk IA
    Endocr Relat Cancer; 2006 Dec; 13(4):1017-31. PubMed ID: 17158752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
    Malinowski DP
    Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gene expression profiling of ER+ breast cancers: to discriminate the poor prognosis tumors or to define the most suitable treatment?].
    Chanrion M; Darbon JM
    Bull Cancer; 2008 May; 95(5):513-8. PubMed ID: 18541515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.
    Dahl E; Kristiansen G; Gottlob K; Klaman I; Ebner E; Hinzmann B; Hermann K; Pilarsky C; Dürst M; Klinkhammer-Schalke M; Blaszyk H; Knuechel R; Hartmann A; Rosenthal A; Wild PJ
    Clin Cancer Res; 2006 Jul; 12(13):3950-60. PubMed ID: 16818692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
    Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
    Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
    Brenton JD; Carey LA; Ahmed AA; Caldas C
    J Clin Oncol; 2005 Oct; 23(29):7350-60. PubMed ID: 16145060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of gene-expression profiling and its clinical use in breast cancer.
    Stadler ZK; Come SE
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):1-11. PubMed ID: 18614375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer.
    Chow LW
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S13-7. PubMed ID: 20374025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Histopathologic diagnosis of luminal and basal type breast cancer].
    Sarcević B
    Acta Med Croatica; 2008 Oct; 62(4):427-30. PubMed ID: 19205420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of gene transcript signatures predictive for estrogen receptor and lymph node status using a stepwise forward selection artificial neural network modelling approach.
    Lancashire LJ; Rees RC; Ball GR
    Artif Intell Med; 2008 Jun; 43(2):99-111. PubMed ID: 18420392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in projecting clustering results across gene expression-profiling datasets.
    Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
    J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.